A detailed history of Sather Financial Group Inc transactions in Eli Lilly & CO stock. As of the latest transaction made, Sather Financial Group Inc holds 1,741 shares of LLY stock, worth $1.36 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
1,741
Previous 1,763 1.25%
Holding current value
$1.36 Million
Previous $1.6 Million 3.38%
% of portfolio
0.11%
Previous 0.12%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$772.14 - $960.02 $16,987 - $21,120
-22 Reduced 1.25%
1,741 $1.54 Million
Q2 2024

Jul 24, 2024

BUY
$724.87 - $909.04 $115,979 - $145,446
160 Added 9.98%
1,763 $1.6 Million
Q1 2024

May 07, 2024

SELL
$592.2 - $792.28 $177,660 - $237,684
-300 Reduced 15.76%
1,603 $1.25 Million
Q4 2023

Jan 26, 2024

BUY
$525.19 - $619.13 $2,625 - $3,095
5 Added 0.26%
1,903 $1.11 Million
Q3 2023

Oct 19, 2023

SELL
$434.7 - $599.3 $16,518 - $22,773
-38 Reduced 1.96%
1,898 $1.02 Million
Q2 2023

Jul 20, 2023

SELL
$350.74 - $468.98 $59,625 - $79,726
-170 Reduced 8.07%
1,936 $907,000
Q1 2023

Apr 18, 2023

BUY
$310.63 - $364.82 $13,978 - $16,416
45 Added 2.18%
2,106 $723,000
Q4 2022

Jan 20, 2023

SELL
$321.55 - $374.67 $77,493 - $90,295
-241 Reduced 10.47%
2,061 $0
Q2 2022

Jul 20, 2022

BUY
$278.73 - $327.27 $72,748 - $85,417
261 Added 12.79%
2,302 $746,000
Q1 2022

Apr 29, 2022

BUY
$234.69 - $291.66 $31,917 - $39,665
136 Added 7.14%
2,041 $584,000
Q4 2021

Jan 24, 2022

BUY
$224.85 - $279.04 $78,697 - $97,664
350 Added 22.51%
1,905 $526,000
Q3 2021

Nov 02, 2021

BUY
$221.6 - $272.71 $344,588 - $424,064
1,555 New
1,555 $359,000
Q3 2017

Nov 14, 2017

SELL
$77.07 - $85.54 $323,694 - $359,268
-4,200 Closed
0 $0
Q2 2017

Aug 15, 2017

BUY
N/A
4,200
4,200 $346,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $740B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Sather Financial Group Inc Portfolio

Follow Sather Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sather Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Sather Financial Group Inc with notifications on news.